Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Annotation

Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis . 2007 May ; 195(5):406-14. PubMed Abstract

Comments on Paper and Primary News
Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Sarah Yates
Submitted 1 June 2007 Posted 1 June 2007

Discontinuation studies like Wunderink's are problematic because it is difficult to tell whether relapse is due to genuine recurrence reflecting original natural history, or drug withdrawal. There is little evidence to show what length of tapering protocol might be most appropriate.

To illustrate the difficulty, consider what happens in Tourette syndrome:

"Rapid discontinuation from drugs such as haloperidol, pimozide, and fluphenazine may lead to severe withdrawal effects. In general, discontinuation of medication may lead to 2 to 3 months of increased symptoms. Thus, if those medications are withdrawn, it cannot be expected that the patient's "real" status will be visible for quite a while. Some patients may improve for a few weeks after neuroleptic discontinuation and then worsen after an additional week or so, remain worse for a while, and then gradually improve. Side effects such as cognitive blunting, troubles with memory, feelings of dullness, poor motivation, school and sociable phobias, excessive appetite, and sedation may lift rather...  Read more


View all comments by Sarah Yates

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Marvin Herz
Submitted 4 June 2007 Posted 4 June 2007
  I recommend this paper

It is clear that some patients with schizophrenia can do well off antipsychotic medication most of the time. The challenge is how to identify them and develop strategies to minimize the possibility of full relapse. The Harrow study is very helpful in that regard. A small percentage of first break patients will not have another relapse after recovering from the episode even if they are off medication. The benefits and risks should be discussed with the patient if he/she wants to be off medication.

In my studies, I have identified patient characteristics that help identify which patient might succeed off medication, including first break. They should have insight into their illness and not lose it if they begin to relapse; be capable of recognizing their early warning signs of impending relapse and be willing to take APDs when this occurs (having a cooperative family helps); no history of violence or suicidality during prior psychotic episodes; no history of rapid decompensation in prior episodes; and not a drug abuser. Patients should be taught to recognize early signs of...  Read more


View all comments by Marvin Herz

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Sarah Yates
Submitted 6 June 2007 Posted 8 June 2007

Marvin Herz writes, "A small percentage of first break patients will not have another relapse after recovering from the episode even if they are off medication. The benefits and risks should be discussed with the patient if he/she wants to be off medication."

But surely the bigger issue is that patients can have relapses whether on antipsychotics or not. The real question is who will, taking into account serious physical side effects, significant increased mortality, and cognitive effects, benefit overall and long term from antipsychotics.

Well, maybe not the 20 percent or so who show little or no functional response; they are getting a heap of side effects for minimal benefit. And for those in the middle, i.e., excluding those 20 percent who would have gotten better anyway—leaving 60 percent of the total—well, we do not know, because discontinuation effects fatally flaw the maintenance studies. It is impossible to accurately judge the impact of discontinuation on relapse rates (see previous post). Discontinuation studies also miss out those who are...  Read more


View all comments by Sarah Yates

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Marvin Herz
Submitted 12 June 2007 Posted 13 June 2007

Sarah Yates dismisses the importance of maintenance medication in preventing relapse, because patients relapse on or off medication. It is known that the majority of patients alternate between acute episodes (relapse) and periods of full or partial remission. There have been randomized controlled studies comparing an intermittent (targeted) medication strategy with maintenance medication which have all found that intermittent medication results in much higher relapse rates over 2 years. In our study, it was 30 percent for intermittent and 16 percent for those on maintenance (Herz et al., 1991). Other studies have found even larger differences favoring maintenance.

Relapses are highly undesirable for patients and their families. After each relapse, re-hospitalizations are lengthier and patients may not recover to their previous level of symptoms and functioning. However, a German study found no benefit in maintenance medication for first break patients (Gaebel et al., 2002). My...  Read more


View all comments by Marvin Herz

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Patricia Estani
Submitted 13 June 2007 Posted 18 June 2007
  I recommend this paper

I think that the question of this research news—must the administration of antipsychotic drugs be forever?—is one of the most important questions that really began an excellent debate among the scientific community.

The article by Dr. J. Bola (Bola, 2006; also see SRF related news story) is a really excellent article in this regard, not only for a clinical discussion but also for a research discussion. I think that the scientific community must take these ideas as one of the most important issues for future discussion in the field of schizophrenia research.

View all comments by Patricia Estani


Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Vittorio Di Michele
Submitted 20 June 2007 Posted 20 June 2007
  I recommend this paper

In my opinion, these papers confirm and disclose, with stringent scientific methodology, a wide range of phenomena, until now not adequately investigated and understood, observed in countries with a very strong commitment to community-based mental health care, like Italy. The following phenomena listed are typical of a community-based mental health system, which is specifically organized by rules and recommendations of the National Plan of Italian Government:

1. A large proportion of schizophrenia-schizoaffective patients isn’t ever admitted in a psychiatric inpatient unit.

2. The antipsychotic mean doses are lower in Italy than in the U.S., and many patients show a “satisfactory” response at dosage much lower than expected.

3. Many patients and their caregivers (usually parents or partner) manage their antipsychotic daily dosage by themselves, adjusting the dosage according to their needs. Surprisingly, very often this management works!

4. Psychosocial interventions reduce the need for antipsychotics and are currently delivered in a special unit of Mental...  Read more


View all comments by Vittorio Di Michele

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Sarah Yates
Submitted 22 June 2007 Posted 22 June 2007

I am not dismissing the importance of maintenance medication; I am saying that the randomized controlled studies quoted by Marvin Herz, which show advantages of maintenance over intermittent medication, are so fundamentally flawed by inadequate tapers and potential discontinuation effects that it is difficult to interpret the results (see my previous posts).

In addition, design of the studies gives an apparently distorted effect, because significant numbers of patients, up to 40 percent, who continue to experience psychotic symptoms whilst taking antipsychotics are not included in the trial, so one is examining a subset of “good” drug responders, giving a false picture of antipsychotic efficacy. The evidence shows that a significant proportion of “good” responders would have recovered without drug treatment in the first place. No drug treatment is not equivalent to treatment and withdrawal.

For these reasons the clearest way to truly assess the benefit of long-term maintenance medication is to use placebo-controlled RCTs (Bola,...  Read more


View all comments by Sarah Yates

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  William Carpenter, SRF Advisor (Disclosure)
Submitted 22 June 2007 Posted 22 June 2007
  I recommend this paper

I have been interested in this issue for a long time, first as a treatment issue and later as an ethics problem. Key aspects of the discussions are often misconceptualized. My view is as follows:

1. The issue is never drugs or no drugs, but rather how to integrate therapies.

2. Continuous medication is not the only active pharmacotherapy strategy. Targeted antipsychotic treatment is effective (less so than continuous for relapse prevention, but perhaps better for negative symptoms and similar to overall outcome measures). A targeted approach may be optimal for patients who refuse continuous medication, for patient subjects in off-medication protocols for research, and for a subgroup with good prognostic indicators who want to consider managing their recovery process off medication. The targeted approach addresses relapse prevention by intervening early in exacerbation and by assuring continuity of clinical care (see Buchanan and Carpenter, 1996, for overview).

3. Off-medication research is feasible and ethically defensible. The Helsinki Declaration was a flawed...  Read more


View all comments by William Carpenter

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Shitij Kapur (Disclosure)
Submitted 28 June 2007 Posted 28 June 2007

Have followed the comments above with great interest. I come to this from the perspective of someone who studies the mechanisms of antipsychotics—usually focusing on the acute and the shorter-term, but find myself increasingly getting interested in the longer-term issues.

I think there can be little denying that antipsychotics administered to those acutely psychotic lead to less distress for those treated and better ability for the rest of us to work with them. The short-term mechanism (D2 blockade) and short-term gains are rather undeniable.

The question is, what are the longer-term trade-offs? This remains a complex question. From a biological perspective the introduction of any drug, including antipsychotics, is an external challenge for the body. The body responds by trying to establish homeostasis and compensate for this challenge. We have shown both in animals (Samaha et al., 2007) and in humans (Silvestri et al., 2000) that, in certain situations and certain...  Read more


View all comments by Shitij Kapur

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  James C. Matthews
Submitted 28 June 2007 Posted 29 June 2007

The whole idea of "to drug or not to drug" is rather new to me. As a schizoaffective patient for many years who has been mostly compliant with my psychiatrist's direction, I can only say that this might only add confusion to the issue. I attend a lot of discussion and support groups for people with bipolar disorder and schizophrenia. The message I hear the most is to keep taking one's meds. The reason that this message is so often repeated is simply that it is so frequently rejected or ignored by so many patients. The biggest reason for relapse and continued problems is noncompliance. Once patients learn that other patients are experimenting with discontinuing medication, you will simply have more cases of noncompliance. Most patients don't live in a vacuum and most don't necessarily do what they are told. While many lack insight, they do not lack free will.

View all comments by James C. Matthews


Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Sarah Yates
Submitted 2 July 2007 Posted 2 July 2007

Thanks to all for an interesting debate.

William Carpenter writes, "The issue is never drugs or no drugs, but rather how to integrate therapies."

The therapeutic issue remains drug or no drug if one assumes appropriate social and emotional support will be available to all from diagnosis. At any given point in management the decision that really matters, and is directly influenced by the psychiatrist, is drug or no drug. All other specific therapies are of unproven utility (with the possible exception of cognitive behavior therapy), and can be administered concurrently with drugs. So what therapy is it one is integrating drug use with? I think the issue is whether the long-term goal is to maximize drug use, or minimize drug use, both in terms of numbers of individuals treated, and dose (including number of antipsychotics prescribed concurrently), and duration once treated.

My fundamental position is that careful assessment of long-term data suggests that the goal should be to minimize use of antipsychotics for psychosis including schizophrenia, and in most cases...  Read more


View all comments by Sarah Yates

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Wolfgang Gaebel
Submitted 13 July 2007 Posted 13 July 2007
  I recommend this paper

Efficacy of Treatment Has to Be Related to Safety
The three articles and their summary provided by the Schizophrenia Research Forum address very important questions in long-term treatment of schizophrenia. Due to the efficacy of (first- and second-generation) antipsychotics (FGAs, SGAs) florid psychotic symptoms mostly remit under initiated and maintained treatment in the acute and stabilization phase. However, this mental illness is in most cases (about 80 percent) characterized by symptom recurrence or relapse, and long-term (low-dose) maintenance treatment is indicated to prevent relapse and maintain or improve patients' level of functioning. Like nearly all drugs, antipsychotics can also cause side effects, like extrapyramidal reactions, tachycardia, hypotension, lethargy, impotence, or hyperprolactinaemia (mainly by FGAs), agranulocytosis (Clozapine), weight gain, or metabolic effects (mainly discussed for the newer SGAs). However, contrary to the SRF summary, serious side effects are rather infrequent and uncommon. Nevertheless, to avoid (potential) harm for...  Read more


View all comments by Wolfgang Gaebel

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  William Carpenter, SRF Advisor (Disclosure)
Submitted 14 July 2007 Posted 16 July 2007
  I recommend this paper

Sarah Yates provides an interesting and informative comment touching on many relevant issues—please read. My thoughts on a couple of these issues are as follows:

1. Minimizing or maximizing antipsychotic drug administration may be a public health issue, but it is not the concept for treating an individual. The issue is optimizing drug therapy (as well as other therapies). In this regard, the evidence base is very weak and practice is probably very bad. Drugs do not come to market with good evidence for optimal dosing even in the acute situation. The doctor's responsibility will be to develop recommendations at each phase of illness based on relatively little information. And the available data will be on groups of patient subjects in illness phase and other circumstances different from the individual being treated.

2. Optimizing will depend on many things, but decisions on how to approach this are developed in the doctor/patient relationship in the broad context of the recovery process. Here an appreciation of risks and benefits is ascertained with attention to...  Read more


View all comments by William Carpenter

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Sarah Yates
Submitted 17 July 2007 Posted 18 July 2007

I welcome much of what William Carpenter has to say, though, as he points out, all of it is up for debate, as there are no certainties. However, I think it a little harsh to state, "As a clinical concept, the ‘no drug’ proposition is applicable only if based on an anti-drug ideology." No drug ever, for anyone under any circumstances, yes: this is an ideology. To raise the legitimate concern that once an individual is started on drugs it may be very hard to ever stop them, at least for some individuals, is not an ideology. It is a pragmatic concern, from which follows the premise that if it is possible to avoid drugs, it might well be a good idea to do so, and the long-term outcome might be better. As discussed previously, there is evidence to suggest this is not such a silly idea as many suppose. Seikkula is not an ideologist in the sense that patients sometimes do go on antipsychotics, on a needs basis.

In my own case, I tapered from 1.5 mgs risperidone to 0.25 mgs every third day, over nearly a year, although clearly I was on a very low dose for most of that time. (You...  Read more


View all comments by Sarah Yates

Primary News: Antipsychotic Maintenance Treatment: Must It Be Forever?

Comment by:  Cenk Tek
Submitted 26 July 2007 Posted 26 July 2007
  I recommend this paper

I believe the jury is out to decide if long-term antipsychotic treatment is hazardous or not in terms of brain biology. The new generation of antipsychotics clearly increases the risk for other medical problems, thus the re-emerging interest in targeted antipsychotic treatments.

Nobody likes to use a medication all the time. I found most of my patients to be reluctantly compliant on their medications after many self-trials of no medication periods with fairly dramatic psychosocial consequences.

In my experience, the main determinant of success of targeted antipsychotic treatment is not the severity of symptoms such as delusions, but if and how fast insight is lost. There are clear subgroups where the first sign of a relapse is quick loss of insight, while others may keep partial insight throughout relapse of other symptoms. If the desire, and origins of the desire to go off medications, are well addressed in therapy, the second group does enjoy medication-free periods, if not complete medication-free life, albeit almost always with residual symptoms.

Please note...  Read more


View all comments by Cenk Tek
Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


 
 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
 
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright